Advertisement
Screener

VISTAGEN THERAPEUTICS, INC. (VTGN) Stock Issued During Period, Value, Employee Stock Purchase Plan

2.8 / 5 stars · 68/120 Roast Me

VISTAGEN THERAPEUTICS, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan

New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.

  • VISTAGEN THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $74.00K, a 54.04% decline year-over-year.
  • VISTAGEN THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $70.00K, a 38.05% decline year-over-year.
  • VISTAGEN THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $161.00K, a 82.95% increase year-over-year.
  • VISTAGEN THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-12-31 was $113.00K, a 2725.00% increase year-over-year.
  • VISTAGEN THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2026 was $231.00K, a 14.93% increase from fiscal 2025.
  • VISTAGEN THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $201.00K, a 2412.50% increase from fiscal 2024.
  • VISTAGEN THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $8.00K, a 87.30% decline from fiscal 2023.
  • VISTAGEN THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $63.00K, a 36.56% decline from fiscal 2022.
Period endStock Issued During Period, Value, Employee Stock Purchase Plan 3 monthStock Issued During Period, Value, Employee Stock Purchase Plan 12 month
2026-06-30$74.00K
10-Q · filed 2026-08-14
2026-03-31$231.00K
10-K · filed 2026-06-15
2025-12-31$70.00K
10-Q · filed 2026-02-12
2025-06-30$161.00K
10-Q · filed 2026-08-14
2025-03-31$201.00K
10-K · filed 2026-06-15
2024-12-31$113.00K
10-Q · filed 2026-02-12
2024-06-30$88.00K
10-Q · filed 2026-02-12
2024-03-31$8.00K
10-K · filed 2025-06-17
2023-12-31$4.00K
10-Q · filed 2025-02-13
2023-06-30$4.00K
10-Q · filed 2025-02-13
2023-03-31$63.00K
10-K · filed 2024-06-11
2022-12-31$7.00K
10-Q · filed 2024-02-13
2022-06-30$56.10K
10-Q · filed 2024-02-13
2022-03-31$99.30K
10-K · filed 2023-06-28
2021-12-31$67.80K
10-Q · filed 2023-02-07
2021-06-30$31.60K
10-Q · filed 2023-02-07
2021-03-31$26.20K
10-K · filed 2022-06-23
2020-12-31$13.60K
10-Q · filed 2022-02-10
2020-06-30$12.60K
10-Q · filed 2022-02-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
MUSTANG BIO, INC. (MBIO)United States$0.013B
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13
Tempest Therapeutics, Inc. (TPST)United States$0.013B
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
BIOVIE INC. (BIVI)United States$0.012B
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
ADIAL PHARMACEUTICALS, INC. (ADIL)United States$0.012B
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
Tvardi Therapeutics, Inc. (TVRD)United States$0.014B